Clinical Research Directory
Browse clinical research sites, groups, and studies.
Aleniglipron Phase 2 Body Composition Study
Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Summary
This is a randomized, double-blind, placebo-controlled study evaluating the effects of aleniglipron on body composition in participants living with obesity. Participants will be randomized to aleniglipron or placebo in a ratio of 5:1. Participants will receive multiple ascending QD doses of aleniglipron or placebo in titration steps of 4 weeks duration for a total of 40 weeks of treatment.
Official title: A Phase 2, Randomized, Double-blind, Placebo-controlled, Study Evaluating the Effects of Aleniglipron (GSBR-1290) on Body Composition in Participants Living With Obesity (Body Mass Index ≥ 30 kg/m2)
Key Details
Gender
All
Age Range
18 Years - 79 Years
Study Type
INTERVENTIONAL
Enrollment
71
Start Date
2025-08-15
Completion Date
2026-10
Last Updated
2026-03-03
Healthy Volunteers
No
Interventions
aleniglipron or placebo
Drug: aleniglipron administered orally Drug: placebo administered orally
Locations (11)
Research Site
Phoenix, Arizona, United States
Research Site
Chicago, Illinois, United States
Research Site
Richfield, Minnesota, United States
Research Site
City of Saint Peters, Missouri, United States
Research Site
Rochester, New York, United States
Research Site
Wilmington, North Carolina, United States
Research Site
Norman, Oklahoma, United States
Research Site
Moncks Corner, South Carolina, United States
Research Site
North Charleston, South Carolina, United States
Research Site
Austin, Texas, United States
Research Site
San Antonio, Texas, United States